Congress quietly loosens rules for remote psychiatric drug prescribing
H.R. 6994 — Mental Health TALK SAFE Act of 2026 · Filed by Neal Dunn (R-FL) · 1 cosponsor · Introduced Jan 9, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands telehealth prescribing of controlled substances for mental health treatment and opioid use disorder by allowing psychiatrists and psychiatric nurses to prescribe via video consultation after a single telehealth evaluation, and permits psychiatrists licensed in one state to practice across state lines without additional licensure. It also restricts pharmacists' ability to refuse filling such prescriptions and preempts state laws that would limit these practices. The primary beneficiaries are telehealth companies offering remote psychiatric care and the practitioners they employ.
Why we flagged it
The bill's core function is to create a regulatory pathway that exempts telehealth entities from standard controlled-substance prescribing safeguards (in-person evaluation, state licensure, pharmacist refusal rights) while imposing detailed structural requirements on telehealth operators themselves. This is a sector-specific deregulation designed to enable rapid scaling of remote psychiatric prescribing.
What the text implies
- The bill permits controlled-substance prescribing after a single telehealth evaluation, bypassing the traditional in-person evaluation requirement that has been a cornerstone of DEA oversight for decades. This may increase risk of inappropriate prescribing, drug-seeking behavior, and diversion.
- Pharmacists are prohibited from refusing to fill prescriptions based solely on telehealth origin, even if they have clinical concerns about validity. The bill requires them to attempt validation but does not give them final authority to refuse—shifting liability and clinical judgment away from the dispensing professional.
The full analysis lists 5 implications of this text.
Who stands to gain
telehealth companies specializing in psychiatric care; pharmaceutical companies (mental health and opioid-use-disorder medications); psychiatrists and psychiatric nurses employed by or contracting with telehealth entities